Driving and benzodiazepine use: Evidence that they do not mix

CNS Drugs

Volumn 10, Issue 5, 1998, Pages 383-396

  Van Laar, Margrietha W ^a   Volkerts, Edmund R ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; DIAZEPAM; FLUNITRAZEPAM; FLURAZEPAM; HYPNOTIC SEDATIVE AGENT; LOPRAZOLAM; LORMETAZEPAM; NEUROLEPTIC AGENT; NITRAZEPAM; OPIATE DERIVATIVE; PSYCHOTROPIC AGENT; TEMAZEPAM;

DRIVING ABILITY; DRUG MECHANISM; DRUG USE; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TRAFFIC ACCIDENT;

EID: 0031725024     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199810050-00007     Document Type: Review

References (78)

1. Gold MS, Miller NS, Stennie K, et al. Epidemiology of benzodiazepine use and dependence. Psychiatr Ann 1995; 25 (3): 146-8
2. Schwartz M, Landerman R, George LK, et al. Benzodiazepine anti-anxiety agents: prevalence and correlates of use in a southern community. Am J Public Health 1991; 81 (5): 592-6
3. Hering RMC. Gencesmiddelen als determinant van ongevallen. Utrecht: Univ. of Utrecht, 1994
4. Pelissole A, Boyer P, Lepine JP, et al. Epidemiologie de la consommation des anxiolytiques et des hypnotiques en France et dans le monde. Encephale 1996; 22 (3): 187-96
5. Vermeeren A, De Gier JJ, O'Hanlon JF. Methodological guidelines for experimental research on medicinal drugs affecting driving performance: an international expert survey. Maastricht: Univ. of Limburg, 1993
6. Christopherson AS, Beylich KM, Bjorneboe A, et al. Prevalence of alcohol and drugs in blood samples from Norwegian drivers in road traffic accidents. In: Kloeden CN, McLean AJ, editors. Proceedings of the 13th International Conference on Alcohol, Drugs and Traffic Safety; 1995 Aug 13-18: Adelaide. Adelaide: University of Adelaide, 1995
7. Parliament of Victoria, Final report of the Road Safety Committee into the effects of drugs (other than alcohol) on road safety in Victoria. Vol. 1 and 2. Victoria. Victorian Government Printer, 1996
8. Lillsunde P, Korte T, Michelson L, et al. Drug usage of drivers suspected of driving under the influence of alcohol and/or drugs: a study of one week's samples in 1979 and 1993 in Finland. Forensic Sci Int 1996; 77: 119-29
9. Gjerde H, Beylich KM, Morland J. Incidence of alcohol and drugs in fatally injured car drivers in Norway. Accid Anal Prev 1993; 25 (4): 479-83
10. Augsburger M, Rivier L. Drugs and alcohol among suspected impaired drivers in Canton de Vaud (Switzerland). Forens Sci Int 1997; 85: 95-104
11. Skurtveit S, Christophersen AS, Morland J. Kjoring under pevirkning av benzodiazepiner: fylkesforskjeller i salgel reflekteres blant bilforere mistenkt for kjorinh i parvirket tilstand. Tidsskr Nor Laegeforen 1995; 115 (2): 200-3
12. Robertson MD, Drummer OH. Responsibility analysis: a methodology to study the effects of drugs in driving. Accid Anal Prev 1994; 26 (2): 243-7
13. Morkenstein FR, Crowther RF, Shumate RP, et al. The role of the drinking driver in traffic accidents. Blutalkohol 1974; 11 Suppl. 1: 1-13
14. Krüger HP, Schulz E, Magerl H. The German Roadside Survey 1992-1994. Saliva analyses from an unselected drivers population: licit and illicit drugs. In: Kloeden CN, McLean AJ, editors. Proceedings of the 13th International Conference on Alcohol Drugs and Traffic Safety; 1995 Aug 13-18: Adelaide. Adelaide: University of Adelaide, 1995
15. Skegg DCG, Richards SM, Doll R. Minor tranquillisers and road accidents. BMJ 1979; 1: 917-9
16. Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol 1992; 136 (7): 873-83
17. Leveille SG, Buchner DM, Koepsell TD, et al. Psychoactive medications and injurious motor vehicle collisions involving older drivers. Epidemiology 1994; 5 (6): 591-8
18. Neutel CI. Risk of traffic accident injury after a prescription for a benzodiazepine. Ann Epidemiol 1995; 5 (3): 239-44
19. Drummer O. Drugs and accident risk in fatally-injured drivers. In: Kloeden CN, McLean AJ, editors. Proceedings of the 13th International Conference on Alcohol, Drugs and Traffic Safety; 1995 Aug 13-18: Adelaide. Adelaide: University of Adelaide, 1995
20. Lagier G. Are benzodiazepines a risk factor in road accidents? Benzodiazepine/Driving Collaborative Group. Drug Alcohol Depend 1993; 33: 19-22
21. Sjögren H. Injuries among elderly [dissertation]. Umea (Sweden): Univ. of Umea, 1994
22. Johansson K. Older automobile drivers: medical aspects [dissertation]. Stockholm: Karolinska Institute, 1997
23. Koelega HS. Benzodiazepines and vigilance performance: a review. Psychopharmacology 1989; 98: 145-56
24. Saletu B, Pakesch G. Recent advances in the clinical pharmacology of benzodiazepines. Part I: pharmacokinetics: part II: pharmacodynamics. Hum Psychopharmacol 1987; 2: 3-10, 61-84
25. Johnson LC, Chernik DA. Sedative-hypnotics and human performance. Psychopharmacol 1982; 76: 101-13
26. Smiley A. Effects of minor tranquilizers and antidepressants on psychomotor performance. J Clin Psychiatry 1987; 48 (12): 22-8
27. O'Hanlon JFO, De Gier JJ, editors. Drugs and driving. London, Philadelphia: Taylor and Francis, 1986
28. Volkerts ER, Van Laar MW, Van Willigenburg APP, et al. A comparative study of on-the-road and simulated driving performance after nocturnal treatment with lormetazepam 1 mg and oxazepam 50 mg. Hum Psychopharmacol 1991; 7: 297-309
29. O'Hanlon JF, Vermeeren A, Uiterwijk MMC, et al. Anxiolytics' effects on the actual driving performance of patients and healthy volunteers in a standardised test. Neuropsychobiol 1995; 31: 81-8
30. Gudgeon AC, Hindmarch I. The effects of 1,4 and 1,5 benzodiazepines on aspects of car driving behaviour: a preliminary investigation. Med Science 1980; 8: 709-10
31. Whetherell A. Individual and group effects of 10 mg diazepam on drivers' ability, confidence and willingness to act in a gap- judging task. Psychopharmacol 1979; 10: 259-67
32. Taylor JL, Tinklenberg JR. Cognitive impairment and benzodiazepines. In: Meltzer HY, editor. Psychopharmacology: the third generation. New York: Raven Press, 1987: 1449-54
33. Linnoila M, Erwin CW, Brendle A, et al. Psychomotor effects of diazepam in anxious patients and healthy volunteers. J Clin Psychopharmacol 1983; 3: 88-96
34. Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmacol 1980; 10: 189-209
35. Volkerts ER, O'Hanlon JFO. Hypnotics' residual effects on driving performance. In: O'Hanlon JFO, De Gier JJ, editors. Drugs and driving. London, Philadelphia: Taylor and Francis, 1986: 123-35
36. Brookhuis KA, Volkerts ER, O'Hanlon JF. Repeated dose effects of lormetazepam and flurazepam upon driving performance. Eur J Clin Pharmacol 1990; 38: 1-5
37. O'Hanlon JF, Volkerts ER, Brookhuis KA, et al. Repeated dose effects of nitrazepam and temazepam upon actual driving performance. Groningen: Traffic Research Centre, University of Groningen, 1985
38. Woods JH, Winger G. Abuse liability of flunitrazepam. J Clin Psychopharmacol 1997; 17 Suppl. 2: 1S-57S
39. Bond A, Lader M. Aftereffects of sleeping drugs. In: Wheatly D, editor. Psychopharmacology of sleep. New York: Raven Press, 1981: 177-97
40. Kunsman GW, Manno JE, Manno BR, et al. The use of microcomputer-based psychomotor tests for the evaluation of benzodiazepine effects on human performance: a review with emphasis on temazepam. Br J Clin Pharmacol 1992; 34: 289-301
41. Roth T, Roehrs T. Determinants of residual effects of hypnotics. Accid Anal Prev 1985; 17 (4): 291-6
42. Schmidt U, Brendemuhl D, Ruther E. Aspects of driving after hypnotic therapy with particular reference to temazepam. Acta Psychiatr 1986; 332: 112-8
43. Moskowitz H, Linnoila M, Roehrs T. Psychomotor performance in chronic insomniacs during 14-day use of flurazepam and midazolam. J Clin Psychopharmacol 1990; 10: 44S-55S
44. Aranko K, Matilla MJ, Seppala T. Development of tolerance and cross-tolerance to the psychomotor actions of lorazepam and diazepam in man. Br J Clin Pharmacol 1983; 15: 545-52
45. Greenblatt DJ, Shader RI, Abernathy DR. Current status of benzodiazepines. N Engl J Med 1983; 309 (6): 354-8
46. Greenblatt DJ. The pharmacology of benzodiazepines: comments on terminology and sources of data. Psychopharmacol 1995; 118: 119
47. Saletu B, Pakesch G. Recent advances in the clinical pharmcology of benzodiazepines. Part I: pharmacokinetics. Hum Psychopharmacol 1987; 2: 3-10
48. Greenblatt DJ, Shader RI. Benzodiazepines in the elderly: pharmacokinetics and drug sensitivity. In: Sulzman C, Lebowitz BD, editors. Anxiety in the elderly. New York: Springer, 1991
49. Rothschild AJ. Disinhibition, amnestic reactions and other adverse reactions secondary to triazolam: a review of the literature. J Clin Psychiatry 1992; 53: 69-79
50. Riedel WJ, Quasten, Hausen, et al. A study comparing the hypnotic efficacies on actual driving performance of midazolam 15 mg, triazolam 0.5 mg, temazepam 20 mg and placebo in shiftworkers on night duty. Maastricht: Institute for Drugs Safety and Behaviour, University of Limburg: 1988 Nov. Report: IGVG 88-01
51. Nicholson AN. Hynotics and transient insomnia. In: O'Hanlon JFO, De Gier JJ, editors. Drugs and driving. London, Philadelphia (PA): Taylor and Francis, 1986
52. Seppala T, Kortilla S, Hakkinen S, et al. Residual effects and skills related to driving after a single oral administration of diazepam, medazepam or lorazepam. Br J Clin Pharmacol 1976; 3: 831-41
53. Volkerts ER, Abbink F, Van Laar MW, et al. Comparison of the effects of ritanserin 5 mg b.i.d. and lorazepam 1.5 mg b.i.d. upon driving performance in an over-the-road driving test. Utrecht: Netherlands Institute for Drugs and Doping Research, Univ. of Utrecht, 1990
54. Van Leeuwen TH, Verbaten MN, Koelega HS, et al. Effects of bromazepam on single-trial event-related potentials in a visual vigilance task. Psychopharmacol 1992; 106: 555-64
55. Curran V, Schiwy W, Lader M. Differential amnesic properties of benzodiazepines: a dose-response comparison of two drugs with similar elimination half-lives. Psychopharmacol 1987; 92 (3): 358-64
56. Kozena L, Frantik E, Horvath M. Vigilance impairment after a single dose of benzodiazepines. Psychopharmacol 1995; 119 (1), 39-45
57. Hindmarch I. The psychopharmacology of clobazam. Hum Psychopharmacol 1995; 10: S15-25
58. Eysenck MW. Attention and arousal. Berlin, Heidelberg: Springer- Verlag, 1982
59. Pomara N, Deptula D, Singh R, et al. Cognitive toxicity of benzodiazepines in the elderly. In: Salzman C, Lebowitz BD, editors. Anxiety in the elderly. New York: Springer, 1991: 175-96
60. Van Laar MW, Volkerts ER, Van Willigenburg APP. Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients. J Clin Psychopharmacol 1992; 12: 86-95
61. Tyrer P, Tyrer J. Antidepressive drugs for treatment of anxiety disorders- and vice versa. In: Den Boer JA, Sitsen JMA, editors. Handbook of depression and anxiety: a biological approach. New York: Marcel Dekker, 1994; 497-514
62. Wright CE. Clinical pharmacokinetics of alprazolam extended release: a summary. Curr Ther Res 1995; 56 (9), 947-56
63. Ellinwood HE, Heatherly DG, Benzodiazepines, the popular minor tranquilizers: dynamics of effect on driving skills. Accid Anal Prev 1985; 17 (4): 283-90
64. Tala PR, Rollings J, Collins M, et al. Lack of recovery following withdrawal from long-term benzodiazepine use. Psychol Med 1994; 24: 203-13
65. Golombok S, Moodley P, Lader M. Cognitive impairment in long-term benzodiazepine users. Psychol Med 1988; 18: 365-74
66. Gorenstein C, Bernik MA, Pompeia S, et al. Impairment of performance associated with long-term use of benzodiazepines. J Clin Psychopharmacol 1995; 9 (4): 313-8
67. Lucki I, Rickels K, Geller AM. Chronic use of benzodiazepines and psychomotor and cognitive test performance. Psychopharmacol 1986; 88: 426-33
68. Cook PJ. Benzodiazepine hypnotics in the elderly. Acta Psychiatr Scand Suppl 1986; 332: 149-58
69. Greenblatt DJ, Harmatz JS, Shapiro L, et al. Sensitivity to triazolam in the elderly. N Engl J Med 1991; 324: 1691-8
70. Rush CR, Higgins ST, Hughes, et al. Acute behavioral effects of triazolam and caffeine, alone and in combination, in humans. Exp Clin Psychopharmacol 1994; 2 (3): 211-22
71. Roerhs T, Zwijghuizen-Doornenbos A, Smith D, et al. Reversal by caffeine of triazolam-induced impairment of waking function. In: Hindmarch I, Ott H, editors. Benzodiazepine receptor ligands, memory and information processing. Berlin, Heidelberg: Springer-Verlag, 1988: 194-202
72. Ramaekers JG, Ansseau M, Muntjewerff ND, et al. Considering the P450 cytochrome system as determining combined effects of antidepressants and benzodiazepines on actual driving performance of depressed patients. Int Clin Psychopharmacol 1997; 12: 159-69
73. Kroboth PD, Folan MM, Lush RM, et al. Coadministraticin of nefazodone and benzodiazepines: I. Pharmacodynamic assessment. J Clin Psychopharmacol 1995; 15 (5): 306-19
74. Goa KL, Heel RC. Zopiclone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic [updated version published June 1991]. Drugs 1986; 32: 48-65
75. Langtry HD, Benfield P. Zolpidem: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990; 40 (2): 291-313
76. Fulton B, Brogden RN. Buspirone: an updated review of its clinical pharmacology and therapeutic applications. CNS Drugs 1997; 7 (1): 68-88
77. Morton S, Lader M. Alpidem and lorazepam in the treatment of patients with anxiety disorders: comparison of physiological and psychological effects. Pharmacopsychiatry 1992; 25 (4): 177-81
78. Ingum J, Bjorkland R, Bjorneboe A, et al. Relationship between drug plasma concentrations and psychomotor performance after single doses of ethanol and benzodiazepines. Psychopharmacol 1992; 107: 11-7